Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (97)	8/25/2000 11:02:38 PM
From: John Metcalf	Read Replies (1) \| Respond to of 101

Sleep, sleep, sleep -- And then up 15% today. Yesterday Bausch and Lomb (BOL) guided earnings downward. Amongst other factors, they blamed shortfalls on generic competition, and said they would transition to higher-margined products. BOL's statement could be understood to mean that companies like Akorn already have taken market share, and that they intend to walk away from competing in those niches. Sounds good to me!

To: scaram(o)uche who wrote (97)	9/25/2000 9:53:17 AM
From: scaram(o)uche	Respond to of 101

Monday September 25, 7:30 am Eastern Time Press Release SOURCE: Photogen Technologies, Inc. Photogen Enters Into $40 Million Equity Line Financing KNOXVILLE, Tenn., Sept. 25 /PRNewswire/ -- Photogen Technologies, Inc. (Nasdaq: PHGN - news) today announced that it has signed a $40 million equity line with Rochelle, S.A. of London, England. Under the agreement, Rochelle will act as Photogen's exclusive placement agent and will use its best efforts to place Photogen common stock with institutional investors outside the United States. As part of the agreement with Rochelle, Photogen filed a ``shelf'' registration statement with the Securities and Exchange Commission which, when declared effective, would enable the company to issue separate offerings from time to time up to $40 million of its common stock in amounts, at prices, and on terms to be determined at the time of sale. ``This financing gives the company the opportunity and ability to maximize its financial planning and to take advantage of favorable stock prices when obtaining capital. Equally important is the company's ability to seek new funds at its sole discretion and only when needed,'' said Dr. Taffy Williams, president and CEO of Photogen Technologies. ``Together with the company's existing capital, this additional funding will provide the company with the necessary financial resources to aggressively continue its product development programs.'' (snip)